Fig. 8: Schematic of the proposed working model.
The NAFLD metabolic microenvironment activates endogenous palmitate biosynthesis in liver metastatic CRC cells, leading to palmitoylation-dependent EGFR stabilization and plasma membrane localization. Inhibition of FASN with orlistat suppresses NAFLD-driven CRC liver metastasis.
